ARK Genomic Revolution ETF Sees Unusually Large Options Volume (BATS:ARKG)

ARK Genomic Revolution ETF (BATS:ARKG) saw unusually large options trading on Wednesday. Stock investors bought 79,250 put options on the stock. This is an increase of 700% compared to the average volume of 9,906 put options.

ARK Genomic Revolution ETF Price Performance

BATS:ARKG traded down $0.57 during trading hours on Wednesday, hitting $25.59. 4,817,059 shares of the company traded hands. The stock’s fifty day moving average price is $24.75 and its 200-day moving average price is $24.99.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ARKG. JPMorgan Chase & Co. lifted its position in ARK Genomic Revolution ETF by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock worth $75,655,000 after purchasing an additional 698,701 shares during the period. Barclays PLC boosted its position in shares of ARK Genomic Revolution ETF by 252.7% during the 3rd quarter. Barclays PLC now owns 285,108 shares of the company’s stock valued at $7,299,000 after acquiring an additional 204,283 shares in the last quarter. National Bank of Canada FI increased its stake in ARK Genomic Revolution ETF by 28.4% in the third quarter. National Bank of Canada FI now owns 4,155 shares of the company’s stock valued at $106,000 after acquiring an additional 920 shares during the period. Quadrature Capital Ltd bought a new position in ARK Genomic Revolution ETF during the third quarter worth about $1,970,000. Finally, IHT Wealth Management LLC acquired a new position in shares of ARK Genomic Revolution ETF in the 3rd quarter worth approximately $203,000.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.